Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

May 2013 Array BioPharma (ARRY) entered into a Development and Commercialization Agreement with Oncothyreon (ONTY) to collaborate on development and commercialization of ONT380 for the treatment of cancer (previously known also as ARRY380). Upfront Payment Oncothyreon paid Array a onetime fee of $10MM This agreement was terminated effective December 11, 2014. December 2014, Array BioPharma […]

April 2010, Array BioPharma (ARRY) entered into a license agreement with Novartis (NVS) @Novartis which granted Novartis the exclusive worldwide right to develop and commercialize binimetinib, as well as other specified MEK inhibitors. March 2015, Array regained these rights and the 2010 License Agreement terminated on the Effective Date of the Binimetinib Agreement. January 2015, […]

July 2013, Array BioPharma (ARRY) entered into a Drug Discovery Collaboration Agreement with Loxo Oncology (LOXO) @LoxoOncology, and granted Loxo exclusive rights to develop and commercialize certain Array invented compounds targeted at the tropomyosin kinase (“Trk”) family of receptors, including LOXO-101. In April 2014 and again in April 2015, Array and Loxo amended the agreement […]

July 2013, Array BioPharma (ARRY) and Celgene Corporation (CELG) and Celgene Alpine Investment Co., LLC (collectively “Celgene”) entered into a Drug Discovery and Development Option and License Agreement to collaborate on development of an Array invented preclinical development program targeting a novel inflammation pathway. The agreement provides Celgene an option to select multiple clinical development […]

November 2013, Clovis Oncology ($CLVS @ClovisOncology) acquired Ethical Oncology Science, S.p.A. (“EOS”) (known as Clovis Oncology Italy S.r.l., or “COI”) through which the rights to lucitanib were obtained. 2008, EOS had in-licensed exclusive development and commercial rights to lucitanib on a global basis, excluding China, from Advenchen Laboratories. September 2012, EOS entered into a collaboration and license […]

June 2011, Clovis Oncology ($CLVS @ClovisOncology) entered into a license agreement with Pfizer ($PFE @Pfizer) to obtain exclusive global rights to develop and commercialize rucaparib. The rights are exclusive even as to Pfizer and include the right to grant sublicenses. Upfront Payment $7.0MM Milestone 1 $0.4MM, April 2014, for the initiation of ARIEL3 pivotal registration study Milestone 2.0 $88.5MM […]

May 2010, $CLVS entered into an exclusive worldwide license agreement with Avila Therapeutics, Inc. (now Celgene Avilomics Research Inc., part of Celgene Corporation $CELG) to discover, develop and commercialize a covalent inhibitor of mutant forms of the EGFR gene product. As a result of the collaboration contemplated by the agreement, rociletinib was identified as the […]

ZeaChem (Lakewood, CO) a development-stage biofuels company focused on cellulose-based biorefinery processes for producing ethanol, closed a $24M Series C financing. Participants include Birchmere Ventures, Firelake Capital, Globespan Capital Partners, Mohr Davidow Ventures, PrairieGold Venture Partners and Spring Ventures.

OPX Biotechnologies (Boulder, CO) a development-stage biofuels company using synthetic biology to engineer the microbes as a bio-acrylic renewable fuel source, closed a $36.5M Series C financing. Participants include US Renewables Group, DBL Investors, Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group and X/Seed Capital. Thanx for your patience as we catch-up.

Surefire Medical (Westminster, CO) a development-stage medical device company focused on interventional radiology embolic agent delivery, closed a $6.1M Series A financing. Participants include Partisan Management Group and High Country Venture.

Mosaic Bioscience (Boulder, CO) a development-stage synthetic materials company focused on tissue and bone regeneration, closed a $1M Series A financing. Participants include Morgenthaler, HealthCare Ventures and High Country Venture.

Precision Biopsy (Aurora, CO) a development-stage diagnostics company focused on advanced spectroscopy imaging and tissue biopsy for the diagnosis of prostate cancer, closed a $2.5M Series A financing. Participants include Allied Minds.

PanTheryx (Boulder, CO) a commercial-stage pharmaceutical company focused on the acquisition, development and commercialization of pain, inflammation, GERD, rhinitis and peripheral neuropathy products for the Indian healthcare market, closed a $1M Series A financing. Participants were not identified.

« Previous Entries  Next Page »

to top of page...